Medicine and HealthNature Communications
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
M. Terranova-barberio, N. Pawlowska, et al.
This phase II study by Manuela Terranova-Barberio and colleagues reveals exciting insights into the use of epigenetic priming with checkpoint inhibitors in ER-positive breast cancer patients. With a clinical benefit rate of 19% and a novel immune signature identified, the study aims to usher in new possibilities for treatment in PD-L1-negative patients.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma
A. Rezapour, D. Rydbeck, et al.
Medicine and Health
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
F. Ye, S. Dewanjee, et al.
Medicine and Health
Immunotherapy in Breast Cancer: Current Status and Future Directions
C. Valenza, G. Rizzo, et al.
Medicine and Health
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
N. Harbeck, E. Ciruelos, et al.
